ReviewJournal of clinical medicine2025
Enhanced Imaging of Ocular Surface Lesions.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Ocular surface lesions represent a diverse group of pathologies which may be challenging to diagnose clinically. Anterior segment imaging-including anterior segment optical coherence tomography (AS-OCT), optical coherence tomography angiography (OCTA), ultrasound biomicroscopy (UBM), and in vivo confocal microscopy (IVCM)-provides valuable adjunct information for the diagnosis, management, and monitoring of these lesions. The present review aims to provide an update on the principles, current clinical applications, advantages, limitations, and recent advancements in the imaging modalities used for the evaluation of ocular surface lesions. Notable recent advancements include the application of artificial intelligence in the interpretation of AS-OCT, intraoperative use of AS-OCT, the development of three-dimensional UBM, and expanded applications of each modality for a variety of ocular surface lesions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.